Immunic to participate in scientific and industry conferences in may

New york , may 2, 2025 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in may: may 3-6: digestive disease week (ddw). two abstracts discussing immunic's phase 1/1b clinical trial of imu-856, an orally available and systemically acting small molecule modulator that targets sirt6 (sirtuin 6), in patients with celiac disease, have been accepted for poster presentations at this conference in san diego, ca.
IMUX Ratings Summary
IMUX Quant Ranking